1
Ian Alexander McDonald, Elisabeth Albrecht, Benito Munoz: Methods of treating neurodegenerative disorders using protease inhibitors. SIBIA Neurosciences, Stephanie L Heller Ehrman White & McAuliffe Seidman, April 18, 2000: US06051684 (11 worldwide citation)

Methods of use of compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds provided for use in the methods are those of the formula: ##STR1## in which R.sub.1 is preferably 2-methylpropenyl, 2-butenyl, cyclohexyl or cyclohexylmeth ...


2
Ian Alexander McDonald, Elisabeth Albrecht, Benito Munoz, Blake Alan Rowe, Robert Steven Siegel, Steven Lee Wagner: Peptide and peptide analog protease inhibitors. SIBIA Neurosciences, Stephanine L Heller Ehrman White & McAuliffe Seidman, October 5, 1999: US05962419 (9 worldwide citation)

Methods of use of compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds provided for use in the methods are those of the formula: ##STR1## in which R.sub.1 is preferably 2-methylpropenyl, 2-butenyl, cyclohexyl or cyclohexylmeth ...


3
Ian Alexander McDonald, Elisabeth Albrecht, Benito Munoz: Peptide and peptide analog protease inhibitors. Sibia Neurosciences, Stephanie L Heller Ehrman White & McAuliffe Seidman, January 18, 2000: US06015879 (3 worldwide citation)

Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided Among the compounds are those of formulae I and II: ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, cyclohexyl or cyclohexylmethyl; R.sub.2, R ...


4
Ian Alexander McDonald, Elisabeth Albrecht, Benito Munoz: Peptide and peptide analog protease inhibitors. SIBIA Neurosciences, Stephanie L Brown Martin Haller & McClain Seidman, September 8, 1998: US05804560 (2 worldwide citation)

Methods of use of compounds and compounds for the treatment of disorders characterized by the cerebral deposition of amyloid are provided. Among the compounds are those of formulae I and II: ##STR1## in which R.sub.1 is preferably 2-methyl propene, 2-butene, cyclohexyl or cyclohexylmethyl; R.sub.2, ...


5
Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner: Substituted 3-haloallylamine inhibitors of ASSAO and uses thereof. BOEHRINGER INGELHEIM INTERNATIONAL, Michael P Morris, Philip I Datlow, April 5, 2016: US09302986

The preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I: is described. Methods of using compounds of Formula I, or pharmaceutically acceptable salt or derivatives thereof, for the treatment of a variety of indicati ...


6
Mandar Deodhar, Alison Dorothy Findlay, Jonathan Stuart Foot, Wolfgang Jarolimek, Ian Alexander Mcdonald, Alan Duncan Robertson, Craig Ivan Turner: Substituted 3-haloallylamine inhibitors of SSAO and uses thereof. Boehringer Ingelheim International, David L Kershner, December 25, 2018: US10160723

The present invention is related to the preparation and pharmaceutical use of substituted 3-haloallylamine derivatives as SSAO/VAP-1 inhibitors having the structure of Formula I, as defined in the specification: The invention also relates to methods of using compounds of Formula I, or pharmaceutical ...


7
Michael G Palfreyman, Ian Alexander McDonald, Francesco G Salituro, Robert Schwarcz: NMDA antagonists. Merrell Dow Pharmaceuticals, J Michael Dixon, January 16, 1996: US05484814

The present invention is directed to a class of 4,6-disubstituted tryptophan derivatives, 4,6-disubstituted kynurenines, their use as NMDA antagonists and to pharmaceutical compositions containing these compounds.


8
Alan D Robertson, Diego Silva, Ian Alexander McDonald: Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders. Pharmaxis, Venable, Keith G Haddaway, Daniel A Kopp, October 15, 2013: US08557783

Methods of using phosphotetrahydropyran compounds for treatment of fibrotic and scarring disorders, e.g. pulmonary fibrosis, fibrosis associated with surgical procedures, wound healing disorders, scar formation, sclerotic disorders, ocular fibrotic disorders, ocular healing disorders, ocular fibrosi ...


9
Alan D Robertson, Diego Silva, Ian Alexander McDonald: Phosphotetrahydropyran compounds for the treatment of wounds and fibrotic disorders. Pharmaxis, February 23, 2012: US20120045455-A1

Methods of using phosphotetrahydropyran compounds for treatment of fibrotic and scarring disorders, e.g. pulmonary fibrosis, fibrosis associated with surgical procedures, wound healing disorders, scar formation, sclerotic disorders, ocular fibrotic disorders, ocular healing disorders, ocular fibrosi ...